Group by Gene: Include preclinical: Chemotherapy Other DNA Tyrosine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Epigenetics Serine-Threonine Kinase Inhibitors IGF BCL Inhibitors Threonine-Tyrosine Kinase Inhibitors Cyclin Dependent Kinase Inhibitors | Multi-tyrosine kinase inhibitor cabozantinib tablet | regorafenib | DNA synthesis inhibitor, Topoisomerase I inhibitor temozolomide + irinotecan | Alkylating agent melphalan + busulfan | Topoisomerase II inhibitor, RNA synthesis inhibitor dactinomycin | LSD1 inhibitor SP2577 | PD1 inhibitor pembrolizumab | IGF-1R inhibitor | IGF-1R inhibitor CP-751,871 | ASP7487 | GD2 ganglioside inhibitor dinutuximab beta | Alkylating agent, DNA inhibitor trabectedin | Bcl2 inhibitor, Tubulin inhibitor albumin-bound paclitaxel | VDC | OPEC | VC | Chemotherapy GT | VIDE | VAIA | IE | CDK12 inhibitor CDK12 inhibitor | mTOR inhibitor, IGF-1R inhibitor mTOR inhibitor + IGF-1R inhibitor | Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor gemcitabine + docetaxel | Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Topoisomerase I inhibitor cyclophosphamide + ifosfamide + etoposide IV + topotecan | Tubulin polymerization inhibitor, DNA synthesis inhibitor, Topoisomerase I inhibitor temozolomide + irinotecan + vincristine | Alkylating agent, Topoisomerase I inhibitor cyclophosphamide + topotecan | Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization promoter carboplatin + ifosfamide + etoposide IV | RNA polymerase inhibitor, Alkylating agent, Apoptosis stimulant lurbinectedin | EWS-FLI1 inhibitor, ETS inhibitor ONCT-216 | CDK4 inhibitor, CDK6 inhibitor palbociclib | TRAIL R2 agonist AMG 655 | Bcl2 inhibitor venetoclax | MEK inhibitor, Multi-tyrosine kinase inhibitor trametinib + pazopanib | CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor DSP-2033 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||||||||||||||||||||
PTPRD R995C | ||||||||||||||||||||||||||||||||||
PTPRD V253I + PTPRD W775stop | ||||||||||||||||||||||||||||||||||
SPARC overexpression | ||||||||||||||||||||||||||||||||||
TMB-H | ||||||||||||||||||||||||||||||||||
MSI-H/dMMR | ||||||||||||||||||||||||||||||||||
MGMT promoter methylation | ||||||||||||||||||||||||||||||||||
IGF1R underexpression | ||||||||||||||||||||||||||||||||||
IGF1 elevation | ||||||||||||||||||||||||||||||||||
B4GALNT1 expression | ||||||||||||||||||||||||||||||||||
EWSR1-FLI1 fusion | ||||||||||||||||||||||||||||||||||
CD99 positive + VIM positive | ||||||||||||||||||||||||||||||||||
IGF1R expression | ||||||||||||||||||||||||||||||||||
MCL1 amplification | ||||||||||||||||||||||||||||||||||
FUS-ERG fusion | ||||||||||||||||||||||||||||||||||
CDKN2A deletion | ||||||||||||||||||||||||||||||||||
PAK4 deletion | ||||||||||||||||||||||||||||||||||
CASP8 overexpression | ||||||||||||||||||||||||||||||||||
KDM1A overexpression | ||||||||||||||||||||||||||||||||||
FGFR3 amplification + FGFR4 amplification + FLT4 amplification | ||||||||||||||||||||||||||||||||||
BCL2 underexpression |